Quote: Hence the collapse of the stock after the Du decision, and again after being affirmed, as the US market is lost.
Michael, when you state the above, can you clarify if this is your belief from a legal perspective or both a legal and practical perspective?
If Amarin is still the only entity that can grow the reduce-it market thru marketing in the US at this time, then that position still has great value to the generics, no?
If this has been clarified previously and I missed it, my apologies.